Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2334
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults ; volume:14 ; number:1 ; day:15 ; month:3 ; year:2014 ; pages:1-16 ; date:12.2014
BMC infectious diseases ; 14, Heft 1 (15.3.2014), 1-16, 12.2014
- Urheber
-
Gillard, Paul
- Beteiligte Personen und Organisationen
-
Chu, Daniel Wai Sing
Hwang, Shinn-Jang
Yang, Pan-Chyr
Thongcharoen, Prasert
Lim, Fong Seng
Dramé, Mamadou
Walravens, Karl
Roman, François
SpringerLink (Online service)
- DOI
-
10.1186/1471-2334-14-142
- URN
-
urn:nbn:de:1111-2016030320412
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gillard, Paul
- Chu, Daniel Wai Sing
- Hwang, Shinn-Jang
- Yang, Pan-Chyr
- Thongcharoen, Prasert
- Lim, Fong Seng
- Dramé, Mamadou
- Walravens, Karl
- Roman, François
- SpringerLink (Online service)
Ähnliche Objekte (12)
The safety and immunogenicity of a MF59-adjuvanted H5N1 prepandemic influenza vaccine in healthy adults primed with homologous or heterologous H5N1 vaccines: an observational study
The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination
M2e nanovaccines supplemented with recombinant hemagglutinin protect chickens against heterologous HPAI H5N1 challenge
Adjuvanted infuenza vaccine dynamics
Adjuvanted influenza vaccine dynamics
Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
A Phase 1 randomized trial of homologous and heterologous filovirus vaccines with a late booster dose
Schedules and programmes
Sustainable Outlay Schedules
A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults
The safety and immunogenicity of a MF59-adjuvanted H5N1 prepandemic influenza vaccine in healthy adults primed with homologous or heterologous H5N1 vaccines: an observational study
The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination
M2e nanovaccines supplemented with recombinant hemagglutinin protect chickens against heterologous HPAI H5N1 challenge
Adjuvanted infuenza vaccine dynamics
Adjuvanted influenza vaccine dynamics
Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
A Phase 1 randomized trial of homologous and heterologous filovirus vaccines with a late booster dose
Schedules and programmes
Sustainable Outlay Schedules
A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults
The safety and immunogenicity of a MF59-adjuvanted H5N1 prepandemic influenza vaccine in healthy adults primed with homologous or heterologous H5N1 vaccines: an observational study
The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination
M2e nanovaccines supplemented with recombinant hemagglutinin protect chickens against heterologous HPAI H5N1 challenge
Adjuvanted infuenza vaccine dynamics
Adjuvanted influenza vaccine dynamics
Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
A Phase 1 randomized trial of homologous and heterologous filovirus vaccines with a late booster dose
Schedules and programmes
Sustainable Outlay Schedules